This company is no longer active
Angion Biomedica Past Earnings Performance
Past criteria checks 0/6
Angion Biomedica has been growing earnings at an average annual rate of 9.2%, while the Pharmaceuticals industry saw earnings growing at 14.8% annually. Revenues have been growing at an average rate of 43.8% per year.
Key information
9.2%
Earnings growth rate
28.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 43.8% |
| Return on equity | -73.4% |
| Net Margin | -4,457.0% |
| Last Earnings Update | 31 Mar 2023 |
Recent past performance updates
Recent updates
Companies Like Angion Biomedica (NASDAQ:ANGN) Could Be Quite Risky
Apr 27
Angion Biomedica (NASDAQ:ANGN) Will Have To Spend Its Cash Wisely
Jan 05We Think Angion Biomedica (NASDAQ:ANGN) Needs To Drive Business Growth Carefully
Sep 11Angion Biomedica GAAP EPS of -$0.30, revenue of $0.7M misses by $0.08M
Aug 15Angion to discontinue phase 2 trial of ANG-3070 in patients with kidney disease
Jun 29We Think Angion Biomedica (NASDAQ:ANGN) Can Afford To Drive Business Growth
Mar 19Angion Biomedica: Selling At Cash Value
Feb 07Angion Biomedica Corp.'s (NASDAQ:ANGN) Intrinsic Value Is Potentially 49% Above Its Share Price
Oct 05We're Hopeful That Angion Biomedica (NASDAQ:ANGN) Will Use Its Cash Wisely
Aug 18Revenue & Expenses Breakdown
How Angion Biomedica makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 23 | 1 | -29 | 14 | 0 |
| 31 Dec 22 | 2 | -39 | 15 | 0 |
| 30 Sep 22 | 28 | -17 | 16 | 0 |
| 30 Jun 22 | 30 | -24 | 16 | 0 |
| 31 Mar 22 | 30 | -32 | 17 | 0 |
| 31 Dec 21 | 28 | -55 | 18 | 0 |
| 30 Sep 21 | 3 | -98 | 17 | 0 |
| 30 Jun 21 | 2 | -100 | 19 | 0 |
| 31 Mar 21 | 2 | -104 | 21 | 0 |
| 31 Dec 20 | 3 | -80 | 18 | 0 |
| 30 Sep 20 | 3 | -67 | 19 | 0 |
| 31 Dec 19 | 1 | -41 | 10 | 0 |
| 31 Dec 18 | 4 | -25 | 5 | 0 |
| 30 Jun 14 | 6 | 0 | 4 | 0 |
| 31 Mar 14 | 6 | 0 | 4 | 0 |
| 31 Dec 13 | 7 | 1 | 4 | 0 |
| 31 Dec 12 | 7 | 0 | 4 | 0 |
Quality Earnings: ANGN is currently unprofitable.
Growing Profit Margin: ANGN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ANGN is unprofitable, but has reduced losses over the past 5 years at a rate of 9.2% per year.
Accelerating Growth: Unable to compare ANGN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ANGN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-6.3%).
Return on Equity
High ROE: ANGN has a negative Return on Equity (-73.37%), as it is currently unprofitable.